Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 188

Results For "AI"

8753 News Found

Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness
News | October 31, 2025

Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness

Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their


Lupin Digital Health launches VITALYFE
Healthcare | October 31, 2025

Lupin Digital Health launches VITALYFE

AI-powered cardiometabolic wellness platform for India’s workforce


BMS’ Cobenfy sees steady start, eyes stronger growth ahead
News | October 31, 2025

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter


Merck’s Capvaxive shows strong momentum amid industry vaccine decline
News | October 31, 2025

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market


Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
Clinical Trials | October 31, 2025

Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia


AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
News | October 31, 2025

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body


GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
News | October 31, 2025

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio